Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications
12:48pm, Monday, 01'st Apr 2024
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
08:00am, Monday, 01'st Apr 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
12:36pm, Thursday, 28'th Mar 2024
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 26'th Mar 2024
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and C
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen)
ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic a
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR O
– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial 1 –
5 Small Drug Stocks to Buy From a Rebounding Industry
09:56am, Thursday, 29'th Feb 2024
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
03:13pm, Wednesday, 28'th Feb 2024
Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflecti
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
08:46am, Wednesday, 28'th Feb 2024
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript
11:18am, Tuesday, 27'th Feb 2024
Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
08:21am, Tuesday, 27'th Feb 2024
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Tuesday, 13'th Feb 2024
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
